Kurk

Idea

Introduction

Pain-killer overuse is a common problem in the developed world, and many inflammatory issues are mistreated. Kurk is a delicious, daily alternative to pharmaceuticals in the management of inflammation-related illnesses (for example, arthritis, inflammatory bowel conditions, skin disorders including acne, cardiovascular disease). Kurk is 100% a natural product made from plants with zero synthetics and our mission is to help millions of people manage common health issues, naturally.

Having each fought and won their own battles with cancer, Dr. Harrison Weisinger and Trent Scanlen together embarked on a personal and professional journey to optimise their health naturally. After studying curcumin - a plant compound in the turmeric plant, the opportunity was clear. Curcumin has breathtaking anti-inflammatory and anti-cancer properties, but is poorly absorbed due to its crystallised form. Research into Curcumin has been booming - rarely is this seen and is an indicator of worldwide interest in this plant compound.

After 4 years of extensive scientific, medical and customer research, across multiple iterations of product development and testing, Kurk was created - our 100% plant-based curcumin drink, designed for maximum taste and absorption.

Using our trademarked MyCelle+™ formulation and manufacturing technology, produced in our own purpose-built lab in Twickenham, we can improve the absorption of difficult plant compounds.

Backed by Tom Hardy, Tinie Tempah and renowned investor Lyndon Lea, we are now looking to increase our investor base and execute on our plan. Our Customers love us and we are proud to have made a real difference in their lives, offering them a natural alternative to standard painkillers.

Substantial accomplishments to date

After 5 years we have built 3 brands and a Bioscience company and own all of our own supply chain and IP. Our team of seasoned entrepreneurs have extensive experience in this industry and all of our focus is on scaling Kurk. Our shareholders receive shares in our holding company that owns the brands and bioscience company.

Working within a disciplined resource allocation we have achieved:

1. We have impressed 33,000+ customers generating £3.3m+* in online sales in UK/EU and Australia. We have had exceptional customer feedback generating 4.5 stars on Trustpilot with over 2000+ reviews.

2. Created a clean processing technique MyCelle+ ™ that has produced a natural curcumin micellar emulsion, MyCurc+™ (without synthetics) and a plant based preservative Phytoarmour ™ with B2B and licensing potential.

3. Launched our new brand Kurk with 3 flavours (online only) with an incredible 53% repeat purchase rate after only 8 months of trading.

4. Established our biotech laboratory in Twickenham to develop and enhance our products and conduct scientific trials for optimised human health.

5. Developed numerous formats (Micellar liquid, gel and powder) using our trademarked micellar curcumin. In the future, this is planned for inclusion into beauty products, pet products, children's vitamins and B2B food and nutraceutical collaborations.

Our Food Scientist Hannah explains why Kurk is different:

* based on unaudited management accounts.

Monetisation strategy

Kurk is a D2C subscription business with thousands of customers using our products as part of their daily health routine. After years of continual testing, we believe we have developed the optimal product to scale - the crucial combination of a high repeat purchase rate, and IP. We now plan to roll out our proven product into retail and new markets.

We have export opportunities worldwide, and an abundance of interest within the scientific, medical and food industry and have ambitious plans to scale.

We are well positioned across three growing markets:

Having funded this company with Founder + Friend's funds, we believe we have the discipline to operate carefully while at the same time achieving maximal gains. We also have an exciting pipeline of products that are now ready for launch worldwide through retail, online and B2B licensing channels.

Use of proceeds

1. Growth (40%) - Execute on our retail rollout plans and drive volume in existing DTC channels.

2. Licensing/ Export (20%) - Supply agreements for human and pet health markets, through existing partnerships in the UK, US, China, EU, UAE and Australia.

3. Product (20%) - We will expand existing range and move pipeline products into production, retail and licensing.

4. R&D (20%) - Evaluate, through medico-scientific collaborations in UK and abroad, the benefits of Kurk in the management of inflammatory conditions, including arthritis, Alzheimer's prevention and gut health.